Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - Karyopharm Therapeutics Inc.Financial_Report.xls
EX-31.1 - EX-31.1 - Karyopharm Therapeutics Inc.d824483dex311.htm
EX-32.1 - EX-32.1 - Karyopharm Therapeutics Inc.d824483dex321.htm
EX-23.2 - EX 23.2 - Karyopharm Therapeutics Inc.d824483dex232.htm
EX-31.2 - EX-31.2 - Karyopharm Therapeutics Inc.d824483dex312.htm
EX-21.1 - EX-21.1 - Karyopharm Therapeutics Inc.d824483dex211.htm
EX-10.16 - EX-10.16 - Karyopharm Therapeutics Inc.d824483dex1016.htm
EX-10.21 - EX-10.21 - Karyopharm Therapeutics Inc.d824483dex1021.htm
EX-10.17 - EX-10.17 - Karyopharm Therapeutics Inc.d824483dex1017.htm
EX-10.22 - EX-10.22 - Karyopharm Therapeutics Inc.d824483dex1022.htm
10-K - 10-K - Karyopharm Therapeutics Inc.d824483d10k.htm

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the following Registration Statements:

 

  (1) Registration Statement (Form S-3 No. 333-201366) of Karyopharm Therapeutics Inc. and

 

  (2) Registration Statement (Form S-8 No. 333-194746) of Karyopharm Therapeutics Inc.;

of our report dated March 13, 2015, with respect to the consolidated financial statements of Karyopharm Therapeutics Inc. included in this Annual Report (Form 10-K) of Karyopharm Therapeutics Inc. for the year ended December 31, 2014.

/s/ Ernst & Young LLP

Boston, Massachusetts

March 13, 2015